Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

J B Vermorken, F Peyrade, J Krauss, R Mesía, E Remenar, T C Gauler, U Keilholz, J P Delord, P Schafhausen, J Erfán, T H Brümmendorf, L Iglesias, U Bethe, C Hicking, P M Clement, J B Vermorken, F Peyrade, J Krauss, R Mesía, E Remenar, T C Gauler, U Keilholz, J P Delord, P Schafhausen, J Erfán, T H Brümmendorf, L Iglesias, U Bethe, C Hicking, P M Clement

Abstract

Background: Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin. Cilengitide selectively inhibits αvβ3 and αvβ5 integrins and is investigated as a treatment strategy.

Patients and methods: The phase I/II study ADVANTAGE evaluated cilengitide combined with cisplatin, 5-fluorouracil, and cetuximab (PFE) in R/M-SCCHN. The phase II part reported here was an open-label, randomized, controlled trial investigating progression-free survival (PFS). Patients received up to six cycles of PFE alone or combined with cilengitide 2000 mg once (CIL1W) or twice (CIL2W) weekly. Thereafter, patients received maintenance therapy (cilengitide arms: cilengitide plus cetuximab; PFE-alone arm: cetuximab only) until disease progression or unacceptable toxicity.

Results: One hundred and eighty-two patients were treated. Median PFS per investigator read was similar for CIL1W + PFE, CIL2W + PFE, and PFE alone (6.4, 5.6, and 5.7 months, respectively). Accordingly, median overall survival and objective response rates were not improved with cilengitide (12.4 months/47%, 10.6 months/27%, and 11.6 months/36%, respectively). No clinically meaningful safety differences were observed between groups. None of the tested biomarkers (expression of integrins, CD31, Ki-67, vascular endothelial growth factor receptor 2, vascular endothelial-cadherin, type IV collagen, epidermal growth factor receptor, or p16 for human papillomavirus) were predictive of outcome.

Conclusion: Neither of the cilengitide-containing regimens demonstrated a PFS benefit over PFE alone in R/M-SCCHN patients.

Keywords: cetuximab; cilengitide; integrin inhibitor; phase I/II; platinum-based chemotherapy with 5-fluorouracil; recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN).

Figures

Figure 1.
Figure 1.
Disposition of patient populations. ITT, intention-to-treat; PFE, cisplatin, 5-fluorouracil, and cetuximab; PFE + CIL1W: cilengitide once weekly plus PFE; PFE + CIL2W: cilengitide twice weekly plus PFE.
Figure 2.
Figure 2.
Progression-free survival in the ITT population per investigator read (A) and per independent read (B: sensitivity analysis). CI, confidence interval; CIL1W, cilengitide once weekly; CIL2W, cilengitide twice weekly; HR, hazard ratio; ITT, intention-to-treat; PFE, cisplatin, 5-fluorouracil, and cetuximab; PFS, progression-free survival.
Figure 3.
Figure 3.
Overall survival (ITT population). CI, confidence interval; CIL1W, cilengitide once weekly; CIL2W, cilengitide twice weekly; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival; PFE, cisplatin, 5-fluorouracil, and cetuximab.

References

    1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127.
    1. Mesía R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010;21:1967–1973.
    1. Perri F, Longo F, Ionna F, et al. Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck. OncoTargets Ther. 2009;2:243–250.
    1. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl 7):vii252–vii261.
    1. Garmy-Susini B, Varner JA. Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol. 2008;6:155–163.
    1. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci. 2012;33:405–412.
    1. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10:753–768.
    1. Fabricius EM, Wildner GP, Kruse-Boitschenko U, et al. Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp Ther Med. 2011;2:9–19.
    1. Vermorken JB, Guigay J, Mesia R, et al. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer. 2011;104:1691–1696.
    1. Liu PY, Dahlberg S, Crowley J. Selection design for pilot studies based on survival. Biometrics. 1993;49:391–398.
    1. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26:5610–5617.
    1. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712–2718.
    1. Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) Cancer. 2012;118:5601–5607.
    1. Psyrri A, Licitra L, De Blas B, et al. Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the phase III EXTREME trial. Ann Oncol. 2012;23(Suppl 9):ix334–ix335. (abstract 1018O)
    1. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013 .
    1. Isayeva T, Li Y, Maswahu D, et al. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol. 2012;6(Suppl 1):S104–S120.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する